Searchable abstracts of presentations at key conferences in endocrinology

ea0082p16 | Poster Presentations | SFEEU2022

Just another pituitary lesion

Bodi Istavan , Albusaidi Ayisha , Shapey Jonathan , Whitelaw Benjamin , Iftikhar Sahar , Aylwin Simon

Case history: 37F presented with 4 years history of amenorrhea. In addition, she had fatigue, low mood and joint pains. She also had history of polyuria and nocturia. Investigations: Her investigations revealed FSH 2.4 IU/l, LH 1.1 IU/l, Oestradiol < 92 pmol/l, T4 <5 pmol/l, TSH 1.5 mIU/l, IGF-1 13.3 nmol/l (8.5- 30.07), Cortisol 65 nmol/l, Prolactin 68 mIU/l. She was started on Hydrocortisone and levothyroxine. Pituitary MRI revealed a 15 mm les...

ea0081p175 | Pituitary and Neuroendocrinology | ECE2022

Low post-operative cortisol after TSS for pituitary surgery predicts short term but not long term remission

Karunakaran Vanitha , Okasha Mohamed , W Thomas Nick , Barazi Sinan , Maratos Eleni , C Whitelaw Benjamin , Gilbert Jackie , V Carroll Paul , Shapey Jonathan , J B Aylwin Simon

Background: It is generally accepted that a post-operative cortisol of <50 nmol/l is a good predictor of long-term remission following trans-sphenoidal surgery (TSS).Aim: We wished to determine the rate of late recurrence and need for consequent intervention in patients who had initial biochemical remission after TSS for pituitary dependent CushingÂ’s.Methods: We performed a retrospective analysis of our patients who underw...

ea0094p366 | Neuroendocrinology and Pituitary | SFEBES2023

MGMT and MSH2 immunohistochemistry status identifies a pituitary tumour subgroup with excellent progression free survival response to temozolomide: a single centre case series

Whitelaw Ben , Gilbert Jackie , Ling Chuah Ling , Crane James , Dimitriadis Georgios , Thomas Nick , Barazi Sinan , Maratos Eleni , Shapey Jonathan , Laniba Leah , Lazaro Nila , Gordon Nadia , Al-Salihi Omar , King Andrew , Al-Sarraj Safa , Reisz Zita , Bodi Istvan , Al Busaidi Ayisha , U-King-IM Jean-Marie , Aylwin Simon

Temozolomide has an established role as first line chemotherapy for aggressive pituitary adenoma and carcinoma. There are mixed reports whether the MGMT (methylguanine methyltransferase) and mismatch repair protein (MSH2/6) status of a tumour, assessed by immunohistochemistry (IHC) can predict response to temozolomide. This is the first series to assess combined MGMT and MSH2 status. We analysed a retrospective case series of patients treated with temozolomide at our tertiary ...